The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1455
November 10, 2014
View Complete Issue         Table of Contents 2019 
Contrave - A Combination of Bupropion and Naltrexone for Weight Loss
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Contrave - A Combination of Bupropion and Naltrexone for Weight Loss
November 10, 2014 (Issue: 1455)
The FDA has approved a fixed-dose combination of the opioid receptor antagonist naltrexone (ReVia, and others) and the antidepressant and smoking cessation agent bupropion (Wellbutrin SR, Zyban, and others), as Contrave (Orexigen/Takeda) for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Contrave - A Combination of Bupropion and Naltrexone for Weight Loss
Article code: 1455c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.